PULSE NEWS WIRE
Clear, Actionable Intelligence
<2 min
Avg Latency
24/5
Coverage
Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from was processed by Pulse News Wire on January 22, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: January 22, 2026 Cyfuse Biomedical K.K. [4892.T] TOKYO — Cyfuse Biomedical K.K. (4892), represented by Chief Executive Officer Akibashi Shizuka, announced today that its board of directors has resolved to grant voting rights to shareholders who acquired new shares after the record date of December 31, 2025, for the upcoming annual general meeting scheduled for late March 2026. The company will allocate voting rights to Kuraray Co., Ltd., which purchased 352,100 or